Marsh & McLennan Companies (NYSE:MMC – Get Free Report) released its earnings results on Thursday. The financial services provider reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.12, Zacks reports. Marsh & McLennan Companies had a net margin of 16.82% and a return on equity of 32.65%.
Marsh & McLennan Companies Stock Performance
MMC stock traded up $0.64 on Thursday, reaching $219.14. 913,056 shares of the company were exchanged, compared to its average volume of 1,973,350. Marsh & McLennan Companies has a 12 month low of $190.41 and a 12 month high of $235.50. The stock’s fifty day moving average price is $217.95 and its 200 day moving average price is $221.40. The firm has a market capitalization of $107.62 billion, a PE ratio of 26.99, a PEG ratio of 2.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.14 and a quick ratio of 1.14.
Marsh & McLennan Companies Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Thursday, January 30th will be given a dividend of $0.815 per share. This represents a $3.26 dividend on an annualized basis and a yield of 1.49%. The ex-dividend date is Thursday, January 30th. Marsh & McLennan Companies’s dividend payout ratio (DPR) is currently 40.15%.
Analysts Set New Price Targets
Marsh & McLennan Companies Company Profile
Marsh & McLennan Cos., Inc is a professional services firm, which engages in offering clients advice and solutions in risk, strategy, and people. It operates through the Risk and Insurance Services, and Consulting segments. The Risk and Insurance Services segment is involved in risk management activities, as well as insurance and reinsurance broking and services.
Further Reading
- Five stocks we like better than Marsh & McLennan Companies
- What Is WallStreetBets and What Stocks Are They Targeting?
- How Value Investors Find Undervalued Stocks and Build Wealth
- Retail Stocks Investing, Explained
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- Industrial Products Stocks Investing
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
Receive News & Ratings for Marsh & McLennan Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marsh & McLennan Companies and related companies with MarketBeat.com's FREE daily email newsletter.